Ropharma Bras
S.C. Ropharma S.A. operates a chain of pharmacies in Romania. The company distributes over-the-counter medications, food supplements, cosmetics, perfumery, medical devices, dermato-cosmetics, para pharmaceuticals, and other medicines through pharmaceutical warehouses. It also offers cardio-vascular, dermatological, digestive, ophthalmological, osteo-articular, respiratory, urogenital, and diabete… Read more
Ropharma Bras (RPH) - Net Assets
Latest net assets as of December 2024: RON259.34 Million RON
Based on the latest financial reports, Ropharma Bras (RPH) has net assets worth RON259.34 Million RON as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RON947.76 Million) and total liabilities (RON688.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RON259.34 Million |
| % of Total Assets | 27.36% |
| Annual Growth Rate | 10.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9.15 |
Ropharma Bras - Net Assets Trend (2021–2025)
This chart illustrates how Ropharma Bras's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ropharma Bras (2021–2025)
The table below shows the annual net assets of Ropharma Bras from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | RON259.34 Million | +2.97% |
| 2024-06-30 | RON251.85 Million | +7.86% |
| 2023-06-30 | RON233.49 Million | +26.27% |
| 2022-06-30 | RON184.92 Million | +5.73% |
| 2021-06-30 | RON174.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ropharma Bras's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RON30.05 Million | 12.26% |
| Other Components | RON215.17 Million | 87.74% |
| Total Equity | RON245.23 Million | 100.00% |
Ropharma Bras Competitors by Market Cap
The table below lists competitors of Ropharma Bras ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sella Real Estate
TA:SLARL
|
$7.48 Million |
|
First Hartford Corporation
PINK:FHRT
|
$7.48 Million |
|
Planet Image International Limited Class A Ordinary Shares
NASDAQ:YIBO
|
$7.49 Million |
|
Torq Resources Inc
OTCQB:TRBMF
|
$7.49 Million |
|
FIPP S.A.
PA:FIPP
|
$7.48 Million |
|
FACB Industries Incorporated
KLSE:2984
|
$7.48 Million |
|
Prospector Metals Corp.
OTCQB:PMCOF
|
$7.48 Million |
|
KINGKEY I.C. HLD HD-02
F:REC
|
$7.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ropharma Bras's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 240,082,812 to 245,227,946, a change of 5,145,134 (2.1%).
- Net loss of 1,725,895 reduced equity.
- Dividend payments of 4,230,472 reduced retained earnings.
- Other factors increased equity by 11,101,501.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RON-1.73 Million | -0.7% |
| Dividends Paid | RON4.23 Million | -1.73% |
| Other Changes | RON11.10 Million | +4.53% |
| Total Change | RON- | 2.14% |
Book Value vs Market Value Analysis
This analysis compares Ropharma Bras's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.43x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.59x to 0.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | RON0.34 | RON0.20 | x |
| 2022-06-30 | RON0.36 | RON0.20 | x |
| 2023-06-30 | RON0.45 | RON0.20 | x |
| 2024-06-30 | RON0.47 | RON0.20 | x |
| 2025-06-30 | RON0.48 | RON0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ropharma Bras utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.14%
- • Asset Turnover: 1.26x
- • Equity Multiplier: 3.86x
- Recent ROE (-0.70%) is below the historical average (3.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 3.86% | 0.94% | 1.67x | 2.46x | RON-10.74 Million |
| 2022 | 5.80% | 1.38% | 1.82x | 2.31x | RON-7.76 Million |
| 2023 | 3.98% | 1.01% | 1.18x | 3.33x | RON-13.94 Million |
| 2024 | 3.21% | 0.77% | 1.25x | 3.36x | RON-16.29 Million |
| 2025 | -0.70% | -0.14% | 1.26x | 3.86x | RON-26.25 Million |
Industry Comparison
This section compares Ropharma Bras's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
No peer company data available for comparison.